Companies › Aspargo Labs
1 active drug program in 1 registered trial: 1 Phase 1; Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ASP-001.1 (Hezkue Turbo) Phosphodiesterase-5 (PDE-5) inhibitor | PDE5A | Phase 1 | Erectile Dysfunction | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06872866 | ASP-001.1 (Hezkue Turbo) | Phase 1 | Erectile Dysfunction | Genitourinary | Feb 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.